{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T01:10:46Z","timestamp":1658625046588},"reference-count":28,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.acuro.2017.01.003","type":"journal-article","created":{"date-parts":[[2017,2,11]],"date-time":"2017-02-11T03:46:49Z","timestamp":1486784809000},"page":"458-464","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Onabotulinumtoxin A en la incontinencia urinaria: estudio prospectivo de serie de casos"],"prefix":"10.1016","volume":"41","author":[{"given":"A.","family":"Mart\u00edn-Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Fern\u00e1ndez-Mederos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.\u00c1.","family":"Garc\u00eda-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuro.2017.01.003_bib0145","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/nau.20737","article-title":"International Continence Society. Reviewing the ICS 2002 terminology report: The ongoing debate","volume":"28","author":"Abrams","year":"2009","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.acuro.2017.01.003_bib0150","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1001\/jama.300.11.1311","article-title":"Prevalence of symptomatic pelvic floor disorders in US women","volume":"300","author":"Nygaard","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.acuro.2017.01.003_bib0155","doi-asserted-by":"crossref","first-page":"130","DOI":"10.18553\/jmcp.2014.20.2.130","article-title":"Economic burden of urgency urinary incontinence in the United States: A systematic review","volume":"20","author":"Coyne","year":"2014","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.acuro.2017.01.003_bib0160","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/j.1532-5415.2006.00861.x","article-title":"The effect of urinary incontinence on quality of life in older nursing home residents","volume":"54","author":"Dubeau","year":"2006","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.acuro.2017.01.003_bib0165","doi-asserted-by":"crossref","first-page":"291","DOI":"10.18553\/jmcp.2008.14.3.291","article-title":"Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan","volume":"14","author":"D'Souza","year":"2008","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.acuro.2017.01.003_bib0170","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.eururo.2013.10.033","article-title":"An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders","volume":"65","author":"Mangera","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2017.01.003_bib0175","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0022-5347(05)67283-7","article-title":"Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results","volume":"164","author":"Schurch","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2017.01.003_bib0180","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.eururo.2003.12.004","article-title":"European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity","volume":"45","author":"Reitz","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2017.01.003_bib0185","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.juro.2007.01.130","article-title":"Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: Results from a single center, randomized, double-blind, placebo controlled trial","volume":"177","author":"Sahai","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2017.01.003_bib0190","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.juro.2008.03.028","article-title":"Pelvic Floor Disorders Network. Refractory idiopathic urge urinary incontinence and botulinum A injection","volume":"180","author":"Brubaker","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2017.01.003_bib0195","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1016\/j.juro.2009.01.117","article-title":"Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder","volume":"181","author":"Flynn","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2017.01.003_bib0200","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.eururo.2010.11.021","article-title":"EAU guidelines on urinary incontinence","volume":"59","author":"Th\u00fcroff","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2017.01.003_bib0205","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2008.09.009","article-title":"European consensus panel. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: A European consensus report","volume":"55","author":"Apostolidis","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2017.01.003_bib0210","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.acuro.2015.04.001","article-title":"OnabotulinumtoxinA en vejiga hiperactiva: recomendaciones de consenso basadas en la evidencia","volume":"40","author":"Jim\u00e9nez-Cidre","year":"2016","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.acuro.2017.01.003_bib0215","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.maturitas.2011.11.016","article-title":"Overactive bladder: Diagnosis and management","volume":"71","author":"Robinson","year":"2012","journal-title":"Maturitas"},{"key":"10.1016\/j.acuro.2017.01.003_bib0220","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/jech.47.6.497","article-title":"Validation of a severity index in female urinary incontinence and its implementation in an epidemiological survey","volume":"47","author":"Sandvik","year":"1993","journal-title":"J Epidemiol Community Health"},{"key":"10.1016\/j.acuro.2017.01.003_bib0225","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.eururo.2011.12.056","article-title":"Botulinum toxin A versus placebo for refractory detrusor overactivity in women: A randomised blinded placebo-controlled trial of 240 women (the RELAX study)","volume":"62","author":"Tincello","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2017.01.003_bib0230","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1471-2490-14-66","article-title":"A pilot prospective study to evaluate whether the bladder morphology in cystography and\/or urodynamic may help predict the response to botulinum toxin A injection in neurogenic bladder refractory to anticholinergics","volume":"14","author":"\u00c1lvares","year":"2014","journal-title":"BMC Urol"},{"key":"10.1016\/j.acuro.2017.01.003_bib0235","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.eururo.2011.10.028","article-title":"Efficacy and safety of low doses of onabotulinumtoxin A for the treatment of refractory idiopathic overactive bladder: A multicentre, double-blind, randomised, placebo-controlled dose-ranging study","volume":"61","author":"Denys","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2017.01.003_bib0240","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","article-title":"OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: Results of a phase 3, randomized, placebo controlled trial","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2017.01.003_bib0245","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.urology.2012.11.010","article-title":"Long-term efficacy and safety of onabotulinumtoxin A in patients with urinary incontinence due to neurogenic detrusor overactivity: An interim analysis","volume":"81","author":"Kennelly","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.acuro.2017.01.003_bib0250","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: A randomised, double-blind, placebo-controlled trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2017.01.003_bib0255","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/AOG.0b013e31828ca761","article-title":"Severity of urinary incontinence and effect on quality of life in women by incontinence type","volume":"121","author":"Minassian","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.acuro.2017.01.003_bib0260","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/nau.22642","article-title":"Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome","volume":"34","author":"Osborn","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.acuro.2017.01.003_bib0265","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1590\/S1677-5538.IBJU.2014.0221","article-title":"Efficacy of botulinum toxin type A 100 units versus 200 units for treatment of refractory idiopathic overactive bladder","volume":"41","author":"Abdelwahab","year":"2015","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.acuro.2017.01.003_bib0270","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.eururo.2010.09.007","article-title":"Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: Risk factors and influence on treatment outcome","volume":"58","author":"Kuo","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2017.01.003_bib0275","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1464-410X.2012.11282.x","article-title":"Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB)","volume":"111","author":"Mohee","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.acuro.2017.01.003_bib0280","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jfma.2013.10.009","article-title":"Therapeutic outcome and patient adherence to repeated onabotulinumtoxinA detrusor injections in chronic spinal cord-injured patients and neurogenic detrusor overactivity","volume":"114","author":"Chen","year":"2015","journal-title":"J Formos Med Assoc"}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210480617300074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210480617300074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T00:44:12Z","timestamp":1658623452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210480617300074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0210480617300074"],"URL":"https:\/\/doi.org\/10.1016\/j.acuro.2017.01.003","relation":{},"ISSN":["0210-4806"],"issn-type":[{"value":"0210-4806","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Onabotulinumtoxin A en la incontinencia urinaria: estudio prospectivo de serie de casos","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2017.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 AEU. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}